Registry-based randomized clinical trials: Revolutionizing research

Robert Harrington, MD; Stefan James MD, PhD


October 08, 2013

This feature requires the newest version of Flash. You can download it here.

There are few advances in medicine that both improve outcomes and cost less than an established procedure, but the TASTE study--a registry-based clinical trial led by Dr Stefan James in Uppsala, Sweden, and released at the ESC 2013 Congress--has proven an exception to the rule. Dr James joins Dr Bob Harrington to discuss the novel methodology of the trial and how the trialists were able to achieve 100% follow-up with incremental costs that are much less than 10% of those associated with the randomized clinical trial as we currently know it.

See also:
Not a TASTE, Not a Nibble: Thrombectomy a Letdown for PCI-Treated STEMI Patients

Dr James has served as an advisor or consultant and has received grants for clinical research from AstraZeneca, Boston Scientific, Eli Lilly, Medtronic, Terumo, The Medicines Company, Vascular Solutions, and Sanofi.

For Dr Harrington's disclosures, click here.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: